Focus on expanding the delivery of controlled-substances in a microneedle patch. Evaluating potential uses of a microneedle patch for infectious diseases. Strengthening capabilities in the manufacturing of microneedle patches for FDA clinical studies and commercialization. TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)…


Previous articleCybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
Next articleCybin Announces Launch of EMBARK Psychedelic Facilitator Training Program